These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 23535934)

  • 1. Challenges and approaches for the development of safer immunomodulatory biologics.
    Sathish JG; Sethu S; Bielsky MC; de Haan L; French NS; Govindappa K; Green J; Griffiths CE; Holgate S; Jones D; Kimber I; Moggs J; Naisbitt DJ; Pirmohamed M; Reichmann G; Sims J; Subramanyam M; Todd MD; Van Der Laan JW; Weaver RJ; Park BK
    Nat Rev Drug Discov; 2013 Apr; 12(4):306-24. PubMed ID: 23535934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The yin and yang of immunomodulatory biologics: assessing the delicate balance between benefit and risk.
    Danilenko DM; Wang H
    Toxicol Pathol; 2012; 40(2):272-87. PubMed ID: 22222884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tipping the balance towards tolerance: the basis for therapeutic immune modulation by gold?
    Carey JB; Carey MA; Allshire A; van Pelt FN
    Autoimmunity; 2005 Sep; 38(6):393-7. PubMed ID: 16278143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologics for the treatment of autoimmune renal diseases.
    Holdsworth SR; Gan PY; Kitching AR
    Nat Rev Nephrol; 2016 Apr; 12(4):217-31. PubMed ID: 26949177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing the risks of immunosuppression.
    Riminton DS; Hartung HP; Reddel SW
    Curr Opin Neurol; 2011 Jun; 24(3):217-23. PubMed ID: 21519254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologics and postbiologics: novel immunotherapeutics for the induction and maintenance of remission.
    van Eden W; Lisse J; Prakken B; Albani S
    Drug Discov Today; 2010 Jan; 15(1-2):71-7. PubMed ID: 19162218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of immunotherapeutic strategies for the treatment of malignant neoplasia.
    Talmadge JE
    Pathol Immunopathol Res; 1989; 8(5-6):250-75. PubMed ID: 2699034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-molecule control of cytokine function: new opportunities for treating immune disorders.
    Sundberg TB; Xavier RJ; Schreiber SL; Shamji AF
    Curr Opin Chem Biol; 2014 Dec; 23():23-30. PubMed ID: 25222143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy: Off-label biologics use and infection risk-the great unknown.
    Winthrop KL; Smolen JS
    Nat Rev Rheumatol; 2011 Oct; 7(12):685-6. PubMed ID: 21989283
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunomodulating Drugs Based on Poxviral Proteins.
    Shchelkunova GA; Shchelkunov SN
    BioDrugs; 2016 Feb; 30(1):9-16. PubMed ID: 26820996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hazard identification and risk assessment for biologics targeting the immune system.
    Weir AB
    J Immunotoxicol; 2008 Jan; 5(1):3-10. PubMed ID: 18382852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.
    Brennan FR; Cauvin A; Tibbitts J; Wolfreys A
    Drug Dev Res; 2014 May; 75(3):115-61. PubMed ID: 24782266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety assessment of immunomodulatory biologics: the promise and challenges of regulatory T-cell modulation.
    Ponce RA
    J Immunotoxicol; 2011; 8(4):389-97. PubMed ID: 21913866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALSUntangled No. 8: Low dose naltrexone for ALS.
    ALSUntangled Group
    Amyotroph Lateral Scler; 2011 Jan; 12(1):76-8. PubMed ID: 21174518
    [No Abstract]   [Full Text] [Related]  

  • 15. Peptides and peptidomimetics as immunomodulators.
    Gokhale AS; Satyanarayanajois S
    Immunotherapy; 2014; 6(6):755-74. PubMed ID: 25186605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of proteasome inhibitors in oncology and autoimmune diseases.
    Bennett MK; Kirk CJ
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):616-25. PubMed ID: 18729013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A neurologist's guide to safe use of immunomodulatory therapies.
    Vodopivec I; Miloslavsky EM; Kotton CN; Cho TA
    Semin Neurol; 2014 Sep; 34(4):467-78. PubMed ID: 25369442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of biologicals against immune-mediated diseases: do benefits outweigh risks?
    Korkina L; Trakhtman P; De Luca C; Leoni L; Raskovic D; Pastore S
    Drugs Today (Barc); 2010 Feb; 46(2):119-36. PubMed ID: 20393640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in targeting cell surface signalling molecules for immune modulation.
    Yao S; Zhu Y; Chen L
    Nat Rev Drug Discov; 2013 Feb; 12(2):130-46. PubMed ID: 23370250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Response and Safety of Viral Vaccines in Children with Autoimmune Diseases on Immune Modulatory Drug Therapy.
    Tse HN; Borrow R; Arkwright PD
    Expert Rev Vaccines; 2020 Dec; 19(12):1115-1127. PubMed ID: 33507119
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.